APPENDIX A Protection by topical administration of parental C5A against vaginal and rectal HIV challenges in humanized mice. On the left the numbers of mice per treatment are indicated (n = 10) as well as the percentages of human CD45+ and CD45+ CD4+ CD3+ cells. In the middle are the numbers of 10⁵ copies per mL of plasma collected at weeks 1, 2, 3, 6 and 12. On the right are the concentrations of parental C5A SWLRDIWDWICEVLSDFK applied vaginally (A) or rectally (B) 15 min prior to a vaginal (A) and rectal (B) HIV (JR-CSF) challenge.